Latest News and Press Releases

60 Degrees Pharma opens enrollment at Mount Sinai for its B-FREE trial testing tafenoquine in chronic babesiosis, addressing a major unmet medical need.

60 Degrees Pharma reports 223% YoY revenue growth in Q3 2025; advances babesiosis programs with Tulane, Mount Sinai, and MUMS canine designation plans.

First patient in SXTP’s relapsing babesiosis study tested negative post-tafenoquine; FDA Breakthrough request filed, Type B meeting planned 2026.

60 Degrees Pharma (Nasdaq: SXTP) Q2 2025: Supply issue cut revenue, profits rose from cash-pay sales; $1.97M cash extends runway to Mar 2026.

60 Degrees closes $5M public offering with up to $5M more from short-term warrants; funds support working capital and infectious disease R&D.

60 Degrees Pharma (SXTP) prices $5M public offering with potential $5M from warrant exercise; funds to support working capital and corporate purposes.

60 Degrees sets human babesiosis TAM for ARAKODA at $245M annually, $1.1B total through 2035; NDA planned for 2026 pending trial data.

Insurance claims show U.S. babesiosis incidence may be 10x CDC estimates; 60 Degrees links chronic fatigue and plans 2026 NDA for tafenoquine treatment.

60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases.

60 Degrees Pharma CEO Geoff Dow, PhD, will discuss babesiosis threats and therapies at the virtual Healing Lyme Summit, April 15–21